Beslutet från Fed var enhälligt och landade på 25 punkter. Det var Kevin Warshs första höjning som Fed-ordförande, och 16 av de 18 ledamöter som lämnade prognoser räknar med minst en höjning till före årsskiftet.
Three AstraZeneca disclosures – a US approval, an overall survival read-out, and phase III success – dominated an otherwise sharply negative week. All three sector benchmarks declined, where Alzinova's combined phase II start-up and rights issue coincided with the steepest single-stock fall.
För Novos pipeline har tagit stryk på senare tid, med två nya fas III-studier med ziltivekimab i soptunnan. Kandidaten är nu bara en studie från fullständig skrotning – Artemis som kommer att läsas av under första halvåret 2027. Och ziltivekimab är inte det enda som skavt.
AstraZeneca delivered three major disclosures – an EU approval, a phase III readout, and a completed global licence – while BioArctic’s Leqembi secured reimbursement backing in Canada and subcutaneous approval in China. Financing activity was broad-based among Nordic micro-cap companies.
Hittills i år har 25 biotechbolag noterats internationellt, vilket är den högsta antalet sedan 2021, då pandemipengarna sköljde in över sektorn och närmare hundra bolag tog steget till publik handel.
AstraZeneca's phase III CROSSING trial met both co-primary endpoints for Tezspire in eosinophilic esophagitis, while Lytix Biopharma secured FDA feedback clearing a registrational phase III for ruxotemitide in melanoma. Nordic health care equities diverged from US benchmarks, gaining 0.70 per cent as the NBI and XBI both fell more than 2 per cent.
RAS är en familj av gener som fungerar som en cellulär strömbrytare för tillväxt. Vid en RAS-mutation fastnar strömbrytaren i påslaget läge, vilket gör att cellen fortsätter dela sig okontrollerat.
AstraZeneca opened the week with two positive first-line lung cancer readouts and one discontinued trial, disclosed within half an hour of each other. Novonesis and Bavarian Nordic raised full-year guidance and announced buybacks on consecutive days. Nordic health care still gained roughly half as much as the NASDAQ Biotechnology Index.
Sedan pandemin ebbade ut har en fråga hängt över mRNA-fältet: var covidvaccinerna en engångsföreteelse eller har tekniken en bredare potential? Moderna och BioNTech byggde miljardintäkter på covidvaccinerna, men när efterfrågan föll gjorde aktiekurserna detsamma.
Demant raises its full-year outlook after strong H1 results, Zealand Pharma sells rusfertide royalty rights for USD 100 million, XVIVO Perfusion secures CE certificates for its Heart Assist Transport system, and Elicera completes phase I dosing in CARMA with tumour responses in 10 of 11 patients.
Novo Nordisk raised its full-year 2026 adjusted outlook on strong GLP-1 momentum, while BioInvent secured FDA Fast Track designation for BI-1808 in ovarian cancer. Genmab lifted revenue guidance after robust DARZALEX royalties and EPKINLY growth. US indices outperformed sharply – NBI +5.10 per cent, XBI +7.05 per cent – while the Nordic HC SEK GI was near-unchanged at +0.02 per cent.
Novo Nordisk's ziltivekimab produced the expected reductions in free IL-6 and high-sensitivity C-reactive protein but delivered no reduction in major adverse cardiovascular events, at a hazard ratio of 0.99. All three benchmarks closed lower, with the equal-weighted SPDR S&P Biotech ETF falling roughly three and a half times as far as the market-cap-weighted NASDAQ Biotechnology index.
Nordic health care fell 1.61 per cent over the interval, landing between the NASDAQ Biotechnology index and the SPDR S&P Biotech ETF. Beneath the index, dispersion was extreme: nine of the ten largest movers sat inside a plus or minus 26 per cent band, while Alligator Bioscience lost roughly three quarters of its value after discontinuing independent development of mitazalimab and launching a rights issue of approximately SEK 125.6 million.
BioArctic's partner Eisai secured FDA approval for Leqembi Iqlik as a subcutaneous initiation dose, while Novo Nordisk received European Commission authorisation for the Wegovy pill. Nordic health care equities rose 1.82 per cent as US biotech indices declined. Sobi and Orion both raised full-year guidance on strong Q2 earnings.
AstraZeneca and Ionis reported that the phase III CARDIO-TTRansform trial of Wainua (eplontersen) did not meet its primary endpoint in transthyretin-mediated amyloid cardiomyopathy, and the shares closed the week down –10.31 per cent. Biovica expanded a master services agreement with a global pharmaceutical customer and named a new CFO.
Bavarian Nordic secured its fifth global chikungunya vaccine approval via Health Canada. Hansa Biopharma closed the €115 million Idefirix licensing transaction with SERB. Ascendis Pharma presented supportive Week 104 YUVIWEL data. Ascelia Pharma declined 73.8 per cent after receiving a Complete Response Letter from the FDA. All three benchmarks posted solid weekly gains.
PharmaLundensis utvecklar en läkemedelskandidat mot kronisk obstruktiv lungsjukdom (KOL) och kronisk bronkit. Bolaget har varit noterat på Spotlight sedan 2010 och har genom åren genomfört en lång rad emissioner.
BioArctic's fourth BrainTransporter partnership – worth up to USD 800 million with Eli Lilly – headlined a strong week for Nordic health care equities. Sobi received an FDA complete response letter for NASP in uncontrolled gout (CMC issues only), while sector indices rallied broadly, with XBI up over 10 per cent.
Den amerikanska pressen biter. Storbritannien har redan gjort upp med USA – landet betalar mer för läkemedelsinnovation i utbyte mot skydd mot Trumps läkemedelstullar. Även Sverige utreder frågan.
Alvotech closed the week’s largest Nordic life science financing at $165 million, while SynAct Pharma’s phase IIb ADVANCE study narrowly missed its primary endpoint (p=0.06). Oncopeptides entered glioblastoma with a first-patient milestone, and US biotech indices surged – XBI up 5.18 per cent – while the Nordic HC SEK GI declined 1.19 per cent.
Lilly arbetar enligt två parallella modeller som förvärvschef Jacob Van Naarden nyligen beskrev i en intervju med FierceBiotech. Den första handlar om att kasta ut ett brett nät av tidiga, billiga affärer. – The strategy there is, most of these things won’t work, säger Van Naarden.
AlzeCure Pharma surged +262 per cent week-over-week after out-licensing its Alzheimer’s project Alzstatin ACD680 to Eli Lilly in a deal potentially exceeding $1 billion. Novo Nordisk’s Wegovy pill became the first daily oral GLP-1 weight-loss medicine approved in the UK. Bavarian Nordic added DKK 700 million in government vaccine contracts, while Genmab presented strong epcoritamab data at EHA 2026.
Grunden lades av BioArctic. Leqembi, som är resultatet av ett långvarigt samarbete mellan BioArctic och japanska Eisai, är det första läkemedlet som i studier bevisats bromsa förloppet av tidig Alzheimers sjukdom.
Lundbeck's phase IIb bocunebart data open a new migraine mechanism, Alvotech resubmits two U.S. biosimilar applications, Coloplast secures FDA approval for Titan Prime, and Xspray Pharma drops sharply after a Complete Response Letter. All three sector benchmarks finished the week in negative territory.
Lilly halverar sin planerade investering på 2,3 miljarder euro i landet, vilket bland annat innebär att den nya produktionsanläggningen i Alzey – tänkt att tillverka injektionsbehandlingar mot obesitas – nu planeras köras med halv kapacitet och sysselsätta ungefär 500 personer i stället för…
Hansa Biopharma secured a late-breaking oral presentation at ATC for its phase III ConfIdeS kidney transplant data and reported positive European PAES results for Idefirix. Elekta fell 11.4 per cent over the week after Q4 earnings disappointed on both orders and sales. US benchmarks diverged sharply from Nordic health care, with XBI gaining +3.82 per cent while the Nordic HC SEK GI declined –1.58 per cent.
Indexet är uppdelat i nuläge och framtidsförväntningar, och det är nulägesbilden som stärks kraftigt – från att ha klockat in på 57 under Q4 uppgår det nu till 87. Samtidigt ökar framtidsutsikterna marginellt, från 101 till 102.
Vivesto is excluded from the gainers ranking: its 1:100 reverse share split took effect on 20 May, within the measurement week, so its weekly change is not comparable. See Liquidity & Volatility below.
Kina sjösatte 2015 ett genomgripande reformpaket och har sedan dess gått med i ICH och metodiskt byggt upp ett ekosystem av kapital, talang och klinisk infrastruktur.
Bavarian Nordic secured a USD 97 million BARDA contract option and raised full-year guidance, while Novo Nordisk showed that nearly 28 per cent weight loss is achievable in early responders on the higher Wegovy dose. US biotech benchmarks retreated for the week.
Så sent som i mars i år verkade allt gå Diamyd Medicals väg. Fas III-studien DIAGNODE-3 var fullrekryterad och bolaget hade nyligen genomfört en riktad emission på 233 miljoner kronor till en rad namnkunniga amerikanska specialistinvesterare, som Perceptive Advisors, Vestal Point Capital och RA…
Novo Nordisk raised its full-year guidance on the back of Wegovy pill momentum, Zealand Pharma launched a USD 200 million buyback after beating Q1 expectations, and Ascendis Pharma swung to its first operating profit. BioArctic's Leqembi PDUFA was extended to August.
Kampen om injektionspennorna har Eli Lilly redan vunnit, och det på kliniska meriter. Mounjaro/Zepbound har visat starkare viktminskningseffekt än Wegovy, vilket marknaden har belönat. Men på pillerfronten ser det faktiskt annorlunda ut.
Nordic Health Care SEK GI gained 2.29% week-over-week while NBI (–1.69%) and XBI (–2.15%) both declined. Zealand Pharma and Roche advanced petrelintide to phase III; Sobi delivered Q1 revenue of SEK 7,184 million (+24% at constant exchange rates); RaySearch fell 13.1% on a Q1 revenue decline.
Solida siffror. Men inte tillräckligt för att sticka ut i ett allt trängre fält. Wallstreet-analytiker beskriver resultaten som jämförbara med Novo Nordisks Wegovy, men klart under Eli Lillys Zepbound.
Orion received an FDA Orphan Drug Designation and initiated a combination basket trial for ODM-212. Ascendis completed its ADS-to-ordinary-share exchange and called $575 million in convertible notes for redemption. Coloplast cut guidance and wrote down DKK 3.0 billion against Kerecis. All three sector benchmarks fell roughly 3.6–3.9 per cent.
I panelen satt Bita Sehat, partner på Trill Impact, Ted Fjällman vd för Flerie och Daniel Bolanowski, portfolio manager på Arctic Asset Management. Tillsammans dissekerade de klimatet i sektorn, som just nu bäst kan beskrivas som stabilt men extremt selektivt.
Nordic health care gained ground against a backdrop of broader global biotech gains. Photocure posted the week’s largest move after an FDA regulatory disclosure. Roche agreed to acquire Lund-origin SAGA Diagnostics for up to USD 595 million, and Bavarian Nordic added a fourth national approval for its chikungunya vaccine.
Enligt Bloomberg har det danska dermatologibolaget nu valt banker – Danske Bank, JPMorgan och Morgan Stanley – för en möjlig notering på Nasdaq Copenhagen redan i år. LEO Pharma är ingen liten aktör.
Ascendis Pharma dominated the week’s newsflow with three material announcements: YUVIWEL (navepegritide) was granted orphan drug exclusivity by the FDA and is now commercially available in the United States; the company announced plans to list ordinary shares directly on Nasdaq effective 20 April 2026; and new week 52 data from the phase II COACH trial demonstrated benefits beyond linear growth in children with achondroplasia.